Friday, July 10, 2026

pharma · Alzheimer Disease · Pulmonary Fibrosis

Shanghai University of

Shanghai University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Alzheimer Disease, Pulmonary Fibrosis, RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, Chemotherapy, Adjuvant, Neoplasm

Shanghai, China, CN HQ
6 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Shanghai, China, CN
Employees
6
Programs
24
Drugs
33
Patents
0
Clinical program

MWN109 tablet

Phase 1 · small molecule · Overweight or Obesity

MWN109 tablet for Overweight or Obesity is a Phase 1 program (small_molecule) at Shanghai University of Traditional Chinese Medicine with 1 ClinicalTrials.gov record(s).

Internal code MWN109-T-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Shanghai University of Traditional Chinese Medicine
Phase
Phase 1
Modality
small_molecule
Indication
Overweight or Obesity
Status
active
Trials
1

Clinical trials